SoftBank Forges „5 Trillion Health Alliance as Earnings Forecast Plunges 83%
19.05.2026 - 16:12:14 | boerse-global.de
SoftBank Group is betting big on Japanâs healthcare system even as the market braces for a dramatic earnings reversal. The tech conglomerate has joined forces with Fujitsu and SMBC Group to build a national health platform targeting „5 trillion in cost savings, yet the stock has been hammered by a projected 83% collapse in per-share earnings.
The partnership, announced in May 2026, aims to tackle the ballooning medical expenses driven by Japanâs rapidly aging population. Artificial intelligence sits at the core of the initiative, with all patient data remaining inside domestic data centers. SoftBank will funnel users through its PayPay and LINE apps, Fujitsu is developing the data backbone and deploying its proprietary âTakaneâ AI language model, and SMBC Group will handle commercial distribution through its financial network. The consortium expects to attract 60 million users and connect 4,000 clinics.
Strong Results, Darker Outlook
The health push comes days after SoftBank reported fiscal 2026 results that beat profit expectations by a wide margin. Earnings per share hit „874, 44% above analyst consensus, while revenue of „7.8 trillion matched forecasts precisely. Yet the stock fell 6.3% in the week following the May 13 release, sliding to „5,745.
Should investors sell immediately? Or is it worth buying SoftBank?
The culprit is forward guidance. Fifteen analysts now see EPS tumbling to just „149 in fiscal 2027 â an 83% drop from the current level and below earlier estimates of „184. Revenue is expected to rise roughly 6% to „8.29 trillion, outpacing both SoftBankâs historical 5.7% annual growth rate and the sector average of 5.0%. The divergence between topline expansion and bottom-line collapse has left investors deeply unsettled.
Analyst ratings reflect the confusion. Bernstein SocGen launched coverage with a Buy and a „8,200 target, but the stock promptly lost 4.15% on Tuesday amid a broader tech sell-off that dragged the Nikkei to a fourth straight loss. Across the Street, price targets span an extraordinary range: the most bullish call is „8,700, the most bearish „3,140. The average target was recently lifted 11% to „5,971, suggesting some analysts view the earnings cliff as temporary.
Macro Headwinds Add Pressure
Japanâs economy provided little relief. First-quarter GDP grew at an annualized 2.1%, but the Bank of Japan quickly cut its 2026 growth forecast to just 0.5%, reinforcing cautious sentiment among institutional investors. SoftBankâs sprawling portfolio â from Vision Fund stakes to its SoftBank Corp. telecom unit â leaves it exposed to both domestic headwinds and global tech volatility.
The healthcare alliance now must generate tangible service revenue to justify the optimistic end of the analyst spectrum. With EPS forecasts in free fall, the market is demanding proof that SoftBankâs long-term AI and infrastructure bets can outweigh a near-term profit shock. The autumn half-year results will provide the first real test.
Ad
SoftBank Stock: New Analysis - 19 May
Fresh SoftBank information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schÀtzen die Börsenprofis SoftBank Aktien ein!
FĂŒr. Immer. Kostenlos.
